The initial theory behind the creation of SGLT2 inhibitors was to take advantage of the body’s renal glucose management by decreasing SGLT2-mediated glucose reabsorption from the proximal renal tubule, causing glycosuria and controlling hyperglycemia [51]. The gene discussed is SLC5A2; the disease is Hyperglycemia.